Literature DB >> 21123325

IgM anti-β2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus.

Taraneh Mehrani1, Michelle Petri.   

Abstract

OBJECTIVE: Antibodies to ß(2) glycoprotein I (IgG and IgM isotypes) have recently been added to the laboratory criteria of the revised antiphospholipid syndrome classification criteria. We investigated whether IgM anti-ß(2)-glycoprotein I (anti-ß(2)-GPI) is associated with clinical manifestations of systemic lupus erythematosus (SLE).
METHODS: Anti-ß(2)-GPI was measured in 796 patients with SLE (93% women, 53% white, 38% African American, mean age 45 yrs). IgM anti-ß(2)-GPI (> 20 phospholipid units) was found in 16%. Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
RESULTS: As expected, IgM anti-ß(2)-GPI was highly associated with both the lupus anticoagulant and with anticardiolipin. It was associated with transient ischemic attack (OR 2.64, p = 0.04), but not significantly with venous or arterial thrombosis. IgM anti-ß(2)-GPI was protective against lupus nephritis (OR 0.54, p = 0.049), renal damage (p = 0.019), and hypertension (OR 0.58, p = 0.008). This protective effect remained after adjustment for ethnicity.
CONCLUSION: In SLE, IgM anti-ß(2)-GPI is not associated with thrombosis but is protective against lupus nephritis and renal damage. "Natural" autoantibodies of the IgM isotype may have a protective effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123325     DOI: 10.3899/jrheum.100650

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

Review 2.  Protective autoantibodies in the rheumatic diseases: lessons for therapy.

Authors:  Gregg J Silverman; Jaya Vas; Caroline Grönwall
Journal:  Nat Rev Rheumatol       Date:  2013-03-19       Impact factor: 20.543

3.  Antigen-driven induction of polyreactive IgM during intracellular bacterial infection.

Authors:  Derek D Jones; Gregory A DeIulio; Gary M Winslow
Journal:  J Immunol       Date:  2012-06-22       Impact factor: 5.422

4.  IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE.

Authors:  Caroline Grönwall; Ehtisham Akhter; Cheongeun Oh; Rufus W Burlingame; Michelle Petri; Gregg J Silverman
Journal:  Clin Immunol       Date:  2012-01-14       Impact factor: 3.969

5.  Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders.

Authors:  Elif Azarsiz; Gamze Eman; Sanem Eren Akarcan; Ezgi Ulusoy Severcan; Neslihan Karaca; Guzide Aksu; Necil Kutukculer
Journal:  Indian J Clin Biochem       Date:  2017-11-10

Review 6.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

Review 7.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

Review 8.  Renal involvement in antiphospholipid syndrome.

Authors:  Savino Sciascia; Maria José Cuadrado; Munther Khamashta; Dario Roccatello
Journal:  Nat Rev Nephrol       Date:  2014-03-18       Impact factor: 28.314

9.  Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus.

Authors:  Selcan Demir; Jessica Li; Laurence S Magder; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

10.  Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation.

Authors:  Hyemee Joo; Christine Coquery; Yaming Xue; Ingrid Gayet; Stacey R Dillon; Marilynn Punaro; Gerard Zurawski; Jacques Banchereau; Virginia Pascual; Sangkon Oh
Journal:  J Exp Med       Date:  2012-06-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.